APPLICATION NUMBER:

205551Orig1s000

OTHER REVIEW(S)
PMR/PMC Development Template

This template should be completed by the PMR/PMC Development Coordinator and included for each PMR/PMC in the Action Package.

NDA/BLA # 205551
Product Name: TRIUMEQ (abacavir/dolutegravir/lamivudine 600 mg/50 mg /300 mg fixed dose combination (FDC) tablets

PMR/PMC Description: Evaluate the pharmacokinetics, safety and antiviral activity (efficacy) of abacavir/dolutegravir/lamivudine FDC tablets in HIV infected pediatric subjects 12 years to less than 18 years of age and weighing at least 40 kg. The safety and antiviral activity (efficacy) of abacavir/dolutegravir/lamivudine FDC tablets in pediatric subjects should be evaluated for a minimum of 24 weeks. A clinical trial in children 12 to less than 18 years of age and weighing at least 40 kg may not be required if dosing recommendation for the FDC tablets can be supported by pediatric trials already conducted with the individual drug products.

PMR/PMC Schedule Milestones: Final Protocol Submission: 12/31/2017
Study/Trial Completion: 01/31/2022
Final Report Submission: 01/31/2023

1. During application review, explain why this issue is appropriate for a PMR/PMC instead of a pre-approval requirement. Check type below and describe.
   - [ ] Unmet need
   - [ ] Life-threatening condition
   - [ ] Long-term data needed
   - [ ] Only feasible to conduct post-approval
   - [ ] Prior clinical experience indicates safety
   - [ ] Small subpopulation affected
   - [ ] Theoretical concern
   - [x] Other

   Product ready for approval in adults.

2. Describe the particular review issue and the goal of the study/clinical trial. If the study/clinical trial is a FDAAA PMR, describe the risk. If the FDAAA PMR is created post-approval, describe the “new safety information.”
The goal of the study(ies) is to evaluate the safety and efficacy of Triumeq (abacavir/dolutegravir/lamivudine FDC tablets) once daily in pediatric patients 12 to less than 18 years of age and provide a pediatric dosing recommendation.

3. If the study/clinical trial is a PMR, check the applicable regulation.  

*If not a PMR, skip to 4.*

- **Which regulation?**
  - ☑ Accelerated Approval (subpart H/E)
  - ☑ Animal Efficacy Rule
  - ☑ Pediatric Research Equity Act
  - ☑ FDAAA required safety study/clinical trial

- **If the PMR is a FDAAA safety study/clinical trial, does it: (check all that apply)**
  - ☐ Assess a known serious risk related to the use of the drug?
  - ☐ Assess signals of serious risk related to the use of the drug?
  - ☐ Identify an unexpected serious risk when available data indicate the potential for a serious risk?

- **If the PMR is a FDAAA safety study/clinical trial, will it be conducted as:**
  - ☐ Analysis of spontaneous postmarketing adverse events?  
    *Do not select the above study/clinical trial type if:* such an analysis will not be sufficient to assess or identify a serious risk
  
  - ☐ Analysis using pharmacovigilance system?
    *Do not select the above study/clinical trial type if:* the new pharmacovigilance system that the FDA is required to establish under section 505(k)(3) has not yet been established and is thus not sufficient to assess this known serious risk, or has been established but is nevertheless not sufficient to assess or identify a serious risk

  - ☐ Study: all other investigations, such as investigations in humans that are not clinical trials as defined below (e.g., observational epidemiologic studies), animal studies, and laboratory experiments?  
    *Do not select the above study type if:* a study will not be sufficient to identify or assess a serious risk

  - ☐ Clinical trial: any prospective investigation in which the sponsor or investigator determines the method of assigning investigational product or other interventions to one or more human subjects?

4. What type of study or clinical trial is required or agreed upon (describe and check type below)? If the study or trial will be performed in a subpopulation, list here.
Age group 12 to less than 18 years of age and weighing at least 40 kg. Triumeq once daily (abacavir 600mg/ dolutegravir 50mg/ lamivudine 300mg) is currently approved in adults. The individual drug products are also approved as once daily dosing in adults while only dolutegravir is approved as once daily dosing in adolescents (12 to less than 18 years).

The once daily dolutegravir dose is 50 mg in both adults and children 12 to less than 18 years old:

the Sponsor has to conduct a trial evaluating Triumeq in children 12 years of age and older and weighing at least 40kg.

Required

☐ Observational pharmacoepidemiologic study
☐ Registry studies
☒ Primary safety study or clinical trial
☐ Pharmacogenetic or pharmacogenomic study or clinical trial if required to further assess safety
☐ Thorough Q-T clinical trial
☐ Nonclinical (animal) safety study (e.g., carcinogenicity, reproductive toxicology)

Continuation of Question 4

☐ Nonclinical study (laboratory resistance, receptor affinity, quality study related to safety)
☒ Pharmacokinetic studies or clinical trials
☐ Drug interaction or bioavailability studies or clinical trials
☐ Dosing trials
☐ Additional data or analysis required for a previously submitted or expected study/clinical trial (provide explanation)

☐ Meta-analysis or pooled analysis of previous studies/clinical trials
☐ Immunogenicity as a marker of safety
☒ Antiviral activity (efficacy).

Agreed upon:

☐ Quality study without a safety endpoint (e.g., manufacturing, stability)
☐ Pharmacoepidemiologic study not related to safe drug use (e.g., natural history of disease, background rates of adverse events)
☒ Clinical trials primarily designed to further define efficacy (e.g., in another condition, different disease severity, or subgroup) that are NOT required under Subpart H/E
☐ Dose-response study or clinical trial performed for effectiveness
☐ Nonclinical study, not safety-related (specify)
☐ Other

5. Is the PMR/PMC clear, feasible, and appropriate?
   ☒ Does the study/clinical trial meet criteria for PMRs or PMCs?
   ☒ Are the objectives clear from the description of the PMR/PMC?
   ☒ Has the applicant adequately justified the choice of schedule milestone dates?
   ☒ Has the applicant had sufficient time to review the PMRs/PMCs, ask questions, determine feasibility, and contribute to the development process?

PMR/PMC Development Coordinator:
☐ This PMR/PMC has been reviewed for clarity and consistency, and is necessary to further refine the safety, efficacy, or optimal use of a drug, or to ensure consistency and reliability of drug quality.

______________________________
(signature line for BLAs)
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SOHAIL MOSADDEGH
08/20/2014
This template should be completed by the PMR/PMC Development Coordinator and included for each PMR/PMC in the Action Package.

NDA/BLA # 205551
Product Name: TRIUMEQ (abacavir/dolutegravir/lamivudine 600 mg/50 mg /300 mg fixed dose combination (FDC) tablets)

PMR/PMC Description: Conduct a pediatric trial to evaluate the pharmacokinetics, safety and antiviral activity (efficacy) of abacavir/dolutegravir/lamivudine FDC tablets in HIV infected pediatric subjects 6 years to less than 12 years of age and in children older than 12 years of age who weigh less than 40 kg. The safety and antiviral activity (efficacy) of abacavir/dolutegravir/lamivudine FDC tablets in pediatric subjects should be evaluated for a minimum of 24 weeks.

PMR/PMC Schedule Milestones: Final Protocol Submission: 12/31/2017
Study/Trial Completion: 01/31/2022
Final Report Submission: 01/31/2023

1. During application review, explain why this issue is appropriate for a PMR/PMC instead of a pre-approval requirement. Check type below and describe.

- [ ] Unmet need
- [ ] Life-threatening condition
- [ ] Long-term data needed
- [ ] Only feasible to conduct post-approval
- [ ] Prior clinical experience indicates safety
- [ ] Small subpopulation affected
- [ ] Theoretical concern
- [x] Other

Product ready for approval in adults.

2. Describe the particular review issue and the goal of the study/clinical trial. If the study/clinical trial is a FDAAA PMR, describe the risk. If the FDAAA PMR is created post-approval, describe the “new safety information.”

The goal of the study(ies) is to evaluate the safety and efficacy of Triumeq (abacavir/dolutegravir/lamivudine FDC tablets) once daily in pediatric patients 6 to less than 12 years of age and provide a pediatric dosing recommendation.
3. If the study/clinical trial is a **PMR**, check the applicable regulation.
   **If not a PMR, skip to 4.**
   - **Which regulation?**
     - [ ] Accelerated Approval (subpart H/E)
     - [ ] Animal Efficacy Rule
     - [x] Pediatric Research Equity Act
     - [ ] FDAAA required safety study/clinical trial
   - **If the PMR is a FDAAA safety study/clinical trial, does it: (check all that apply)**
     - [ ] Assess a known serious risk related to the use of the drug?
     - [ ] Assess signals of serious risk related to the use of the drug?
     - [ ] Identify an unexpected serious risk when available data indicate the potential for a serious risk?
   - **If the PMR is a FDAAA safety study/clinical trial, will it be conducted as:**
     - [ ] Analysis of spontaneous postmarketing adverse events?
       *Do not select the above study/clinical trial type if:* such an analysis will not be sufficient to assess or identify a serious risk
     - [ ] Analysis using pharmacovigilance system?
       *Do not select the above study/clinical trial type if:* the new pharmacovigilance system that the FDA is required to establish under section 505(k)(3) has not yet been established and is thus not sufficient to assess this known serious risk, or has been established but is nevertheless not sufficient to assess or identify a serious risk
     - [ ] Study: all other investigations, such as investigations in humans that are not clinical trials as defined below (e.g., observational epidemiologic studies), animal studies, and laboratory experiments?
       *Do not select the above study type if:* a study will not be sufficient to identify or assess a serious risk
     - [ ] Clinical trial: any prospective investigation in which the sponsor or investigator determines the method of assigning investigational product or other interventions to one or more human subjects?

4. What type of study or clinical trial is required or agreed upon (describe and check type below)? If the study or trial will be performed in a subpopulation, list here.
Age group: 6 to less than 12 years of age: 12 years and older weighing less than 40 kg:
Triumeq once daily (abacavir 600mg/ dolutegravir 50mg/ lamivudine 300mg) is currently approved in adults. The individual drug products are approved as once daily dosing in adults only.

While twice daily abacavir/lamivudine are already approved for use in children, once daily dosing is not yet available.

Required

☐ Observational pharmacoepidemiologic study
☐ Registry studies
☒ Primary safety study or clinical trial
☐ Pharmacogenetic or pharmacogenomic study or clinical trial if required to further assess safety
☐ Thorough Q-T clinical trial
☐ Nonclinical (animal) safety study (e.g., carcinogenicity, reproductive toxicology)

Continuation of Question 4

☐ Nonclinical study (laboratory resistance, receptor affinity, quality study related to safety)
☒ Pharmacokinetic studies or clinical trials
☐ Drug interaction or bioavailability studies or clinical trials
☐ Dosing trials
☐ Additional data or analysis required for a previously submitted or expected study/clinical trial (provide explanation)

☐ Meta-analysis or pooled analysis of previous studies/clinical trials
☐ Immunogenicity as a marker of safety
☒ Other (provide explanation)
   Antiviral activity (efficacy).

Agreed upon:

☐ Quality study without a safety endpoint (e.g., manufacturing, stability)
☐ Pharmacoepidemiologic study not related to safe drug use (e.g., natural history of disease, background rates of adverse events)
☒ Clinical trials primarily designed to further define efficacy (e.g., in another condition, different disease severity, or subgroup) that are NOT required under Subpart H/E
☐ Dose-response study or clinical trial performed for effectiveness
☐ Nonclinical study, not safety-related (specify)

☐ Other

☐ Nonclinical study, not safety-related (specify)

☐ Other

5. Is the PMR/PMC clear, feasible, and appropriate?
   ☑ Does the study/clinical trial meet criteria for PMRs or PMCs?
   ☑ Are the objectives clear from the description of the PMR/PMC?
   ☑ Has the applicant adequately justified the choice of schedule milestone dates?
   ☑ Has the applicant had sufficient time to review the PMRs/PMCs, ask questions, determine feasibility, and contribute to the development process?

PMR/PMC Development Coordinator:
   ☑ This PMR/PMC has been reviewed for clarity and consistency, and is necessary to further refine the safety, efficacy, or optimal use of a drug, or to ensure consistency and reliability of drug quality.

______________________________
(signature line for BLAs)
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SOHAIL MOSADDEGH
08/20/2014
PMR/PMC Development Template

This template should be completed by the PMR/PMC Development Coordinator and included for each PMR/PMC in the Action Package.

NDA/BLA # 205551
Product Name: TRIUMEQ (abacavir/dolutegravir/lamivudine 600 mg/50 mg /300 mg fixed dose combination (FDC) tablets

PMR/PMC Description: Conduct a pediatric trial to evaluate the pharmacokinetics, safety and antiviral activity (efficacy) of abacavir/dolutegravir/lamivudine FDC tablets in HIV infected pediatric subjects 2 years to less than 6 years of age. The safety and antiviral activity (efficacy) of abacavir/dolutegravir/lamivudine FDC tablets in pediatric subjects should be evaluated for a minimum of 24 weeks.

PMR/PMC Schedule Milestones:  
Final Protocol Submission: 12/31/2017  
Study/Trial Completion: 01/31/2022  
Final Report Submission: 01/31/2023

1. During application review, explain why this issue is appropriate for a PMR/PMC instead of a pre-approval requirement. Check type below and describe.
   - [ ] Unmet need
   - [ ] Life-threatening condition
   - [ ] Long-term data needed
   - [ ] Only feasible to conduct post-approval
   - [ ] Prior clinical experience indicates safety
   - [ ] Small subpopulation affected
   - [ ] Theoretical concern
   - [x] Other

   Product ready for approval in adults.

2. Describe the particular review issue and the goal of the study/clinical trial. If the study/clinical trial is a FDAAA PMR, describe the risk. If the FDAAA PMR is created post-approval, describe the “new safety information.”

   The goal of the study(ies) is to evaluate the safety and efficacy of Triumeq (abacavir/dolutegravir/lamivudine FDC tablets) once daily in pediatric patients 2 to less than 6 years of age and provide a pediatric dosing recommendation.
3. If the study/clinical trial is a **PMR**, check the applicable regulation. 

*If not a PMR, skip to 4.*

- **Which regulation?**
  - [ ] Accelerated Approval (subpart H/E)
  - [ ] Animal Efficacy Rule
  - [x] Pediatric Research Equity Act
  - [ ] FDAAA required safety study/clinical trial

- **If the PMR is a FDAAA safety study/clinical trial, does it: (check all that apply)**
  - [ ] Assess a known serious risk related to the use of the drug?
  - [ ] Assess signals of serious risk related to the use of the drug?
  - [ ] Identify an unexpected serious risk when available data indicate the potential for a serious risk?

- **If the PMR is a FDAAA safety study/clinical trial, will it be conducted as:**
  - [ ] Analysis of spontaneous postmarketing adverse events?
    
    *Do not select the above study/clinical trial type if:* such an analysis will not be sufficient to assess or identify a serious risk

  - [ ] Analysis using pharmacovigilance system?
    
    *Do not select the above study/clinical trial type if:* the new pharmacovigilance system that the FDA is required to establish under section 505(k)(3) has not yet been established and is thus not sufficient to assess this known serious risk, or has been established but is nevertheless not sufficient to assess or identify a serious risk

  - [ ] Study: all other investigations, such as investigations in humans that are not clinical trials as defined below (e.g., observational epidemiologic studies), animal studies, and laboratory experiments?
    
    *Do not select the above study type if:* a study will not be sufficient to identify or assess a serious risk

  - [ ] Clinical trial: any prospective investigation in which the sponsor or investigator determines the method of assigning investigational product or other interventions to one or more human subjects?

4. What type of study or clinical trial is required or agreed upon (describe and check type below)? If the study or trial will be performed in a subpopulation, list here.
Age group 2: to less than 6 years of age.

Truvada once daily (abacavir 600mg/ dolutegravir 50mg/ lamivudine 300mg) is currently approved in adults. The individual drug products are approved as once daily dosing in adults only.

While twice daily abacavir/lamivudine are already approved for use in children, once daily dosing is not yet available.

Required

☐ Observational pharmacoepidemiologic study
☐ Registry studies
☒ Primary safety study or clinical trial
☐ Pharmacogenetic or pharmacogenomic study or clinical trial if required to further assess safety
☐ Thorough Q-T clinical trial
☐ Nonclinical (animal) safety study (e.g., carcinogenicity, reproductive toxicology)

Continuation of Question 4

☐ Nonclinical study (laboratory resistance, receptor affinity, quality study related to safety)
☒ Pharmacokinetic studies or clinical trials
☐ Drug interaction or bioavailability studies or clinical trials
☐ Dosing trials
☐ Additional data or analysis required for a previously submitted or expected study/clinical trial (provide explanation)

☐ Meta-analysis or pooled analysis of previous studies/clinical trials
☐ Immunogenicity as a marker of safety
☒ Other (provide explanation)
   Antiviral activity (efficacy).

Agreed upon:

☐ Quality study without a safety endpoint (e.g., manufacturing, stability)
☐ Pharmacoepidemiologic study not related to safe drug use (e.g., natural history of disease, background rates of adverse events)
☒ Clinical trials primarily designed to further define efficacy (e.g., in another condition, different disease severity, or subgroup) that are NOT required under Subpart H/E
☐ Dose-response study or clinical trial performed for effectiveness
☐ Nonclinical study, not safety-related (specify)

☐ Other

5. Is the PMR/PMC clear, feasible, and appropriate?
   ☒ Does the study/clinical trial meet criteria for PMRs or PMCs?
   ☒ Are the objectives clear from the description of the PMR/PMC?
   ☒ Has the applicant adequately justified the choice of schedule milestone dates?
   ☒ Has the applicant had sufficient time to review the PMRs/PMCs, ask questions, determine feasibility, and contribute to the development process?

PMR/PMC Development Coordinator:
   ☐ This PMR/PMC has been reviewed for clarity and consistency, and is necessary to further refine the safety, efficacy, or optimal use of a drug, or to ensure consistency and reliability of drug quality.

_______________________________________
(signature line for BLAs)
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SOHAIL MOSADDEGH
08/20/2014
DATE: August 12, 2014

TO: Debra Birnkrant, MD
Director
Division of Antiviral Products
Office of New Drugs

FROM: Gajendiran Mahadevan, Ph.D.
GLP Branch
Division of Bioequivalence and GLP Compliance
Office of Scientific Investigations

THROUGH: Charles Bonapace, Pharm.D.
Chief, GLP Branch
Division of Bioequivalence and GLP Compliance
Office of Scientific Investigations

and

William H. Taylor, Ph.D.
Director
Division of Bioequivalence and GLP Compliance
Office of Scientific Investigations

SUBJECT: Review of EIR Covering NDA 205-551, Dolutegravir sodium, Abacavir sulfate and Lamivudine Tablets, 50/600/300 mg

At the request of the Division of Antiviral Products (DAVP), the Division of Bioequivalence and GLP Compliance (DBGLPC) arranged inspections of the clinical and analytical portions of the following in vivo bioequivalence study:

Study Number: ING114580
Study Title: “An evaluation of the bioequivalence of a combined formulated tablet (50/600/300 mg dolutegravir/abacavir/lamivudine) compared to one dolutegravir 50 mg tablet and one EPICOM (600/300 mg abacavir/lamivudine)tablet administered concurrently and the effect of food on
Clinical Inspection:

The inspection of the clinical portion of the study was conducted by Dawn Olenjack (ORA) during June 9-13, 2014 at Quintiles, Overland Park, KS. The inspection included a thorough examination of study records, clinical protocols, protocol amendments, protocol deviations, informed consent forms, SOPs, IRB approvals, case report forms, and interviews/discussions with the firm’s management and staff.

At the conclusion of the inspection, Form FDA 483 was issued (Attachment-1). The response to Form FDA 483 from Quintiles was received by FDA on July 3, 2014 (Attachment-2). Our evaluation of the Form FDA 483 observations and the firm’s response to Form FDA 483 follow:

1) Not all changes in research activity were approved by the IRB prior to implementation. Specifically, you did not obtain IRB approval of Protocol ING114580 Amendment-1 dated 5/31/12 prior to implementing the changes to the original approved protocol dated 5/30/12. You began screening and obtaining consent on 6/19/12 and the first subject was dosed on 7/17/12. Amendment 1 was not approved until 8/9/12. The primary changes in Amendment 1 were increasing the fasting time pre-dose from 6 to 10 hours, removing KIVEXA from the dosing schedule and requiring only EPZICOM be used in the US trial.

Quintiles acknowledged the observation and indicated that they were unaware of the submission error made by the Clinical Study Director (CSD) to the IRB until an internal review of the Investigator Site File on August 9, 2012. The CSD submitted the original protocol instead of protocol amendment-1 (A summary of amendment changes with rationale is found in Attachment-3) by inadvertently saving the electronic file of original protocol as protocol amendment-1 for IRB approval on June 6, 2012. The IRB approved the submission on June 12, 2012 and dosing commenced on July 17, 2012.

The CSD immediately submitted the amended protocol to the IRB on August 9, 2012 upon identification of the submission error. The amended protocol was approved with no changes required to the informed consent on the same day by an expedited IRB review process. As a corrective action, Quintiles updated Work
Instruction PI_WI_PM001, “QOPK Institutional Review Board (IRB) Submission and Approval of Documents” to include the date and document version on all IRB emails, verify the date and document version submitted for all electronic submissions, and compare the IRB approval letter with the submission letter to confirm that the correct documents were reviewed.

DBGLPC Assessment:

In the opinion of this reviewer, submission of the original protocol rather than protocol amendment-1 has no impact on the safety of study subjects.

2) An investigation was not conducted in accordance with the signed statement of the investigator. Specifically, the signed protocol agreement stated “I agree to ensure that all associates, colleagues, and employees assisting in the conduct of the study are informed of their obligations. Mechanisms are in place to ensure that site staff receives the appropriate information throughout the study.”

However, there was no documented protocol training for screener who consented 23 of the 66 subjects enrolled. In addition, Sub-Investigator conducted 7 physical exams (subjects 801023, 801024, 801026, 801029, 801030, 801033, and 8011036) without documented protocol training.

There were specific instructions for the order of study procedures, for drawing and handling blood samples and for volunteer positioning when taking vitals and doing ECGs. However, I identified 5 employees (with initials , , , , and ) who regularly performed the PK sample blood draws and one employee () who performed ECGs that had no record of protocol training. Nine of the 10 subject records, I reviewed for training identified one or more of these individuals. Those subjects were 8010002, 8010003, 801010, 801015, 801016, 801023, 801024, 801029, and 8011036.

Quintiles acknowledged the observation and stated that the deficiency in training documentation was identified at the end of the study by the Interim Screening Supervisor (ISS). A memo was subsequently generated by the ISS indicating the missing training documentation. The firm maintains that all employees were provided study specific training in accordance with the protocol; however, no supporting documents were provided with their response to the Form FDA 483.
As a corrective action, clinical operations staff will be required to document training on all studies prior to the first subject visit effective June 27, 2014. At least 24 hours prior to the first subject visit, the supervisor or designee will review the completed study-specific training documentation to verify that all staff have documented training.

DBGLPC Assessment:

In the opinion of this reviewer, the observation has no impact on the safety of study subjects and the integrity of study data.

Analytical Inspection:

The inspection of the analytical portion of the study was conducted by Corey Reno (ORA) and Gajendiran Mahadevan, Ph.D. (OSI) during 2014, at The inspection included a thorough examination of study records, facilities and equipment, and interviews and discussions with the firm's management and staff. No significant issues were observed and no Form FDA 483 was issued.

Recommendation:

The clinical and analytical data from the audited study were found to be reliable. Therefore, this DBGLPC reviewer recommends the data be accepted for the Agency review.

Gajendiran Mahadevan, Ph.D.
GLP Branch, DBGLPC, OSI

Final Classification:

VAI: Quintile Phase I, Overland Park, KS
FEI: 3010802844

NAI: 
FEI:

CC:
OSI/DBGLPC/Taylor/ Bonapace/Dasgupta/Mahadevan/Dejernett
OSI/DBGLPC/Haidar/Skelly/Choi
CDER/OND/DAVP/Birnkrant/Chikhale/Mosaddegh

Reference ID: 3609108
Page 5 - NDA 205-551, Dolutegravir sodium, Abacavir sulfate, and Lamivudine Tablets sponsored by ViiV Healthcare Company, USA

ORA/KAN-DO/Bous/Olenjack
ORA/MIN-DO/Weisensel/Reno

Draft: GM 07/23/2014
Edit: AG 08/11/2014; CB 08/12/2014

OSI File: BE6699; O:\BE\EIRCOVER\205551.bio.do

ECMS: Cabinets/CDER_OC/OSI/Division of Bioequivalence & Good Laboratory Practice Compliance/INSPECTIONS/BE Program/Analytical Sites/ NDA 205-551_Dolutegravir

FACTS: 8768807

12 Page(s) has been Withheld in Full as b4 (CCI/TS) immediately following this page
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

GAJENDIRAN MAHADEVAN
08/14/2014

ARINDAM DASGUPTA
08/14/2014

CHARLES R BONAPACE
08/14/2014

WILLIAM H TAYLOR
08/15/2014
As requested in the Division of Antiviral Products’ (DAVP) consult dated November 1, 2013, the Office of Prescription Drug Promotion (OPDP) has reviewed the TRIUMEQ prescribing information, medication guide, and carton and container labeling.

OPDP’s comments on the prescribing information are provided below in the proposed substantially complete version of the labeling received via email from DAVP on June 16, 2014.

OPDP reviewed the draft carton and container labeling submitted to the EDR on May 15, 2014, and has no comments at this time.

The Division of Medical Policy Programs and OPDP provided a single, consolidated review of the medication guide on July 2, 2014.

Thank you for your consult. OPDP appreciates the opportunity to provide comments. If you have any questions, please contact Jessica Fox at (301) 796-5329 or at Jessica.Fox@fda.hhs.gov.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JESSICA M FOX
07/02/2014
PATIENT LABELING REVIEW

Date: July 2, 2014

To: Debra Birnkrant, MD
   Director
   Division of Antiviral Products (DAVP)

Through: LaShawn Griffiths, MSHS-PH, BSN, RN
   Associate Director for Patient Labeling
   Division of Medical Policy Programs (DMPP)

From: Karen Dowdy, RN, BSN
   Patient Labeling Reviewer
   Division of Medical Policy Programs (DMPP)
   Jessica Fox, PharmD, RAC
   Regulatory Review Officer
   Office of Prescription Drug Promotion (OPDP)

Subject: Review of Patient Labeling: Medication Guide (MG)

Drug Name (established name): TRIUMEQ (abacavir, dolutegravir, and lamivudine)

Dosage Form and Route: tablets for oral use

Application Type/Number: NDA 205-551

Applicant: GlaxoSmithKline LLC, on behalf of ViiV Healthcare Company
1 INTRODUCTION

On October 22, 2013, GlaxoSmithKline LLC, on behalf of ViiV Healthcare Company, submitted for the Agency’s review New Drug Application (NDA) 205-551 for TRIUMEQ (abacavir, dolutegravir, and lamivudine) tablets, with the proposed indication as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults.

This collaborative review is written by the Division of Medical Policy Programs (DMPP) and the Office of Prescription Drug Promotion (OPDP) in response to the requests by the Division of Antiviral Products (DAVP) on November 1, 2013, for DMPP and OPDP to review the Applicant’s proposed Medication Guide (MG) for TRIUMEQ (abacavir, dolutegravir, and lamivudine) tablets.

2 MATERIAL REVIEWED

• Draft TRIUMEQ (abacavir, dolutegravir, and lamivudine) tablets MG received on October 22, 2013, revised by the Review Division throughout the review cycle, and received by DMPP and OPDP on June 16, 2014.

• Draft TRIUMEQ (abacavir, dolutegravir, and lamivudine) tablets Prescribing Information (PI) received on October 22, 2013, revised by the Review Division throughout the review cycle, and received by DMPP and OPDP on June 16, 2014.

3 REVIEW METHODS

To enhance patient comprehension, materials should be written at a 6th to 8th grade reading level, and have a reading ease score of at least 60%. A reading ease score of 60% corresponds to an 8th grade reading level. In our review of the MG the target reading level is at or below an 8th grade level.

Additionally, in 2008 the American Society of Consultant Pharmacists Foundation (ASCP) in collaboration with the American Foundation for the Blind (AFB) published Guidelines for Prescription Labeling and Consumer Medication Information for People with Vision Loss. The ASCP and AFB recommended using fonts such as Verdana, Arial or APHont to make medical information more accessible for patients with vision loss.

In our collaborative review of the MG we have:

• simplified wording and clarified concepts where possible
• ensured that the MG is consistent with the Prescribing Information (PI)
• removed unnecessary or redundant information
• ensured that the MG is free of promotional language or suggested revisions to ensure that it is free of promotional language
• ensured that the MG meets the Regulations as specified in 21 CFR 208.20
• ensured that the MG meets the criteria as specified in FDA’s Guidance for Useful Written Consumer Medication Information (published July 2006)
4 CONCLUSIONS
The MG is acceptable with our recommended changes.

5 RECOMMENDATIONS
• Please send these comments to the Applicant and copy DMPP and OPDP on the correspondence.
• Our collaborative review of the MG is appended to this memorandum. Consult DMPP and OPDP regarding any additional revisions made to the PI to determine if corresponding revisions need to be made to the MG.

Please let us know if you have any questions.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

KAREN M DOWDY
07/02/2014

JESSICA M FOX
07/02/2014

BARBARA A FULLER
07/02/2014

LASHAWN M GRIFFITHS
07/02/2014
DATE: May 05, 2014

TO: Director, Investigations Branch
Kansas District Office
11630 W. 80th Street
Lenexa, KS - 66214

Director, Investigations Branch
Minneapolis District Office
250 Marquette Avenue, Suite 600
Minneapolis, MN 55401

FROM: Sam H. Haidar, Ph.D., R.Ph.
Chief, Bioequivalence Branch
Division of Bioequivalence and GLP Compliance (DBGLPC)
Office of Scientific Investigations (OSI)

SUBJECT: FY 2014, CDER PDUFA NDA, High Priority Data Validation Inspection, Bioresearch Monitoring, Human Drugs, CP 7348.001

RE: NDA 205-551
DRUG: Dolutegravir sodium (DTG)/Abacavir sulfate (ABC)/Lamivudine (3TC) tablets, 50 mg/600 mg/300 mg
SPONSOR: ViiV Healthcare Company
Research Triangle Park, NC

This memo requests that you arrange for inspections of the clinical and analytical portions of the following bioequivalence (BE) study.

Once you identify an ORA investigator, please contact the DBGLPC point of contact (POC) listed at the end of this assignment memo to schedule the inspection of the analytical site. A DBGLPC scientist will participate in the inspection of the analytical site to provide scientific and technical expertise.

Background materials will be available in ECMS under the ORA folder. The inspections should be completed prior to June 06, 2014.
Do not reveal information about the applicant/sponsor, application number, study to be inspected, drug names, or the study investigator to the sites prior to the start of the inspection. The sites will receive this information during the inspection opening meeting.

The inspection will be conducted under Bioresearch Monitoring Compliance Program CP 7348.001, not under CP 7348.811 (Clinical Investigators).

At the completion of the clinical inspection, please send a scanned copy of the completed sections A and B of this memo to the DBGLPC POC.

Study number: ING114580
Study Title: “An evaluation of the bioequivalence of a combined formulated tablet (50 mg/600 mg/300 mg) dolutegravir/abacavir/lamivudine) compared to one Dolutegravir 50 mg tablet and one EPZICOM (600 mg/300 mg abacavir/lamivudine) tablet administered concurrently and the effect of food on bioavailability of the combined formulation in healthy adult subjects”

Clinical Site: Quintiles Phase I Unit
6700 W. 115th street
Overland Park, KS 66211

Investigator: Ralph Shutz, M.D.

SECTION A – RESERVE SAMPLES

Because this bioequivalence study is subject to 21 CFR 320.38 and 320.63, the site conducting the study (i.e., investigator site) is responsible for randomly selecting and retaining reserve samples from each shipment of drug product provided by the sponsor for subject dosing.

The final rule for "Retention of Bioavailability and Bioequivalence Testing Samples" (Federal Register, Vol. 58, No. 80, pp. 25918-25928, April 28, 1993) specifically addresses the requirements for bioequivalence studies (http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/ucm120265.htm).

Reference ID: 3501194
During the clinical site inspection, please:

☐ Verify that the site retained reserve samples according to the regulations. If the site did not retain reserve samples or the samples are not adequate in quantity, notify the DBGLPC POC immediately.

☐ If the reserve samples were stored at a third party site, collect an affidavit to confirm that the third party is independent from the applicant/sponsor, manufacturer, and packager. Additionally, verify that the site notified the applicant/sponsor, in writing, of the storage location of the reserve samples.

☐ Obtain written assurance from the clinical investigator or the responsible person at the clinical site that the reserve samples are representative of those used in the specific bioequivalence studies, and that samples were stored under conditions specified in accompanying records. Document the signed and dated assurance [21 CFR 320.38(d, e, g)] on the facility's letterhead, or Form FDA 463a Affidavit.

☐ Collect and ship samples of the test and reference drug products in their original containers to the following address:

John Kauffman, Ph.D.
Center for Drug Evaluation and Research
Division of Pharmaceutical Analysis (DPA)
Center for Drug Analysis (HFH-300)
645 S. Newstead Ave
St. Louis, MO  63110
TEL: 1-314-539-2135

SECTION B – CLINICAL DATA AUDIT

Please remember to collect relevant exhibits for all findings, including discussion items at closeout, as evidence of the findings.
During the clinical site inspection, please:

- Confirm the informed consent forms and study records for 100% of subjects enrolled at the site.
- Compare the study report in the NDA submission to the original documents at the site.
- Check for under-reporting of adverse events (AEs).
- Check for evidence of inaccuracy in the electronic data capture system.
- Check reports for the subjects audited.
  - Number of subject records reviewed during the inspection:______
  - Number of subjects screened at the site:______
  - Number of subjects enrolled at the site:______
  - Number of subjects completing the study:______
- Confirm that site personnel conducted clinical assessments in a consistent manner and in accordance with the study protocols.
- Confirm that site personnel followed SOPs during study conduct.
- Examine correspondence files for any applicant or monitor-requested changes to study data or reports.
- Include a brief statement summarizing your findings including IRB approvals, study protocol and SOPs, protocol deviations, AEs, concomitant medications, adequacy of records, inclusion/exclusion criteria, drug accountability documents, and case report forms for dosing of subjects, etc.
- Other comments:

  __________________________________________________________
  __________________________________________________________
  __________________________________________________________
SECTION C – ANALYTICAL DATA AUDIT

Analytical Site: [blank]
Investigator: [blank]
Methodology: UPLC-MS/MS

During the analytical site inspection, please:

□ Examine all pertinent items related to the analytical method used for the measurement of dolutegravir, abacavir and lamivudine concentrations in human plasma.

□ Compare the accuracy of the analytical data in the NDA submission against the original documents at the site.

□ Determine if the site employed a validated analytical method to analyze the subject samples.

□ Compare the assay parameters (such as variability between and within runs, accuracy and precision, etc.) observed during the study sample analysis with those obtained during method validation.

□ Confirm that the accuracy and precision in matrix were determined using standards and QCs prepared from separate stock solutions.

□ Determine if the subject samples were analyzed within the conditions and times of demonstrated stability.

□ Confirm that freshly made calibrators and/or freshly made QCs were used for stability evaluations during method validation.

□ Scrutinize the number of repeat assays of the subject plasma samples, the reason for such repetitions, the SOP(s) for repeat assays, and if relevant stability criteria (e.g., number of freeze-thaw cycles) sufficiently covered the stability of reanalyzed subject samples.

□ Examine correspondence files between the analytical site and the Applicant/sponsor for their content.
Additional instructions to the ORA Investigator:

In addition to the compliance program elements, other study specific instructions may be provided by the DBGLPC POC prior to commencement of the inspection. Therefore, we request that the DBGLPC POC be contacted for any further instructions, inspection related questions or clarifications before the inspection and also regarding any data anomalies or questions noted during review of study records on site.

If you issue Form FDA 483, please forward a copy to the DBGLPC POC. If it appears that the observations may warrant an OAI classification, notify the DBGLPC POC as soon as possible. Remind the inspected site of the 15 business-day timeframe for submission of a written response to the Form FDA 483. In addition, please forward a copy of the written response as soon as it is received to the DBGLPC POC.

DBGLPC POC: Jyoti Patel, Ph.D.
Pharmacologist
Office of Scientific Investigations
Tel: 1-301-796-4617
Fax: 1-301-847-8748
E-mail: jyoti.patel@fda.hhs.gov

DARRTS cc:
CDER OSI PM TRACK
OSI/DBGLPC/Taylor/Haidar/Choi/Patel/Dejernett
OSI/DBGLPC/Bonapace/Mada
CDER/OND/OAP/DAVP/Mosaddegh/Chikhale

Email cc:
ORAKANBIMO@fda.hhs.gov/ Lopicka/Bous/Kuchenthal/Kanion
(BIMO)/Bromley (DIB)
ORAMINBIMO@fda.hhs.gov/Armendariz/Matson (BIMO)/Smith (DIB)
Draft: JBP 05/02/2014
Edit: YMC 5/2/2014; SHH 5/5/14

ECMS: Cabinets/CDER_OC/OSI/Division of Bioequivalence & Good Laboratory Practice Compliance/INSPECTIONS/BE Program/Analytical Sites/
Clinical Sites/Quintiles Phase I Unit, KS

OSI file #: BE 6699; assignment file name: bio205551
FACTS: 8768807
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

----------------------------------------------------
JYOTI B PATEL
05/05/2014

SAM H HAIDAR
05/06/2014
LABEL AND LABELING REVIEW
Division of Medication Error Prevention and Analysis (DMEPA)
Office of Medication Error Prevention and Risk Management (OMEPRM)
Office of Surveillance and Epidemiology (OSE)
Center for Drug Evaluation and Research (CDER)

*** This document contains proprietary information that cannot be released to the public***

Date of This Review: April 22, 2014
Requesting Office or Division: Division of Antiviral Products (DAVP)
Application Type and Number: NDA 205551
Product Name and Strength: Triumeq (Abacavir, Dolutegravir, and Lamivudine) Tablet, 600 mg/50 mg/300 mg
Product Type: Multi-Ingredient
Rx or OTC: Rx
Applicant/Sponsor Name: ViiV Healthcare by GlaxoSmithKline
Submission Date: October 23, 2013
OSE RCM #: 2013-2422
DMEPA Primary Reviewer: Rachna Kapoor, PharmD
DMEPA Team Leader: Yelena Maslov, PharmD
1 REASON FOR REVIEW

This review evaluates the proposed container label, carton labeling, and package insert for Triumeq (Abacavir, Dolutegravir, and Lamivudine) Tablet, NDA 205551, for areas of vulnerability that could lead to medication errors.

2 MATERIALS REVIEWED

We considered the materials listed in Table 1 for this review. The Appendices provide the methods and results for each material reviewed.

<table>
<thead>
<tr>
<th>Material Reviewed</th>
<th>Appendix Section (for Methods and Results)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product Information/Prescribing Information</td>
<td>A</td>
</tr>
<tr>
<td>Labels and Labeling</td>
<td>B</td>
</tr>
</tbody>
</table>

N/A=not applicable for this review

3 OVERALL ASSESSMENT OF THE MATERIALS REVIEWED

DMEPA evaluated labels, labeling, and container closure for this product and identified the following concerns.

This product should be dispensed in its original container to protect it from moisture. However, this information is not explicitly stated on container label and prescriber information labeling. To reinforce the correct dispensing of this product we recommend adding the statement “Dispense in original container” on the container label, carton labeling, and the how supplied / storage and handling section of the package insert.

4 CONCLUSION & RECOMMENDATIONS

DMEPA concludes that the proposed container label, carton labeling, and package insert can be improved from a safety perspective by highlighting important information in the how supplied / storage and handling section of the package insert to reinforce correct dispensing of this product. Additionally, the container label and carton labeling can be improved to ensure safe use of the product.
Based on this review, DMEPA recommends the following be implemented prior to the approval of this NDA:

4.1 **COMMENTS TO THE DIVISION**

   **A. How Supplied / Storage and Handling Section of the Package Insert**
   
   i. Add the statement “Dispense in original container” after the statement “Do not remove desiccant”. This product should be protected from moisture and requires a desiccant. Therefore, this recommendation is to reinforce the correct dispensing of this product.

4.2 **COMMENTS TO THE APPLICANT**

   **A. Container Label Commercial Size and Including Sample**
   
   i. Add the statement in bold font “Dispense in original container” after the statement “Do not remove desiccant”. This product should be protected from moisture and requires a desiccant. Therefore, this recommendation is to reinforce the correct dispensing of this product.

   **B. Carton Labeling Commercial Size and Including Sample**
   
   i. See 4.2.A.i and revise carton labeling accordingly.

   ii. Reduce the size of the purple/pink graphic on the carton labeling to make it less prominent. Per the Draft Guidance: Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors\(^1\), key information such as the proprietary name, established name, strength, and dosage form should be the most prominent information displayed.

\(^1\) 2013 Draft Guidance: *Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors*

APPENDIX A. PRODUCT INFORMATION/PRESCRIBING INFORMATION

Table 2 presents relevant product information for Triumeq that ViiV Healthcare submitted on October 23, 2013.

<table>
<thead>
<tr>
<th>Active Ingredient</th>
<th>Abacavir sulfate, dolutegravir sodium, and lamivudine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indication</td>
<td>A complete regimen for the treatment of human immunodeficiency virus type 1 infection in adults</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>Oral</td>
</tr>
<tr>
<td>Dosage Form</td>
<td>Tablet</td>
</tr>
<tr>
<td>Strength</td>
<td>Abacavir 600 mg / dolutegravir 50 mg / lamivudine 300 mg</td>
</tr>
<tr>
<td>Dose and Frequency</td>
<td>One tablet by mouth once daily</td>
</tr>
<tr>
<td>How Supplied</td>
<td>Bottle of 30 with child-resistant closure</td>
</tr>
<tr>
<td>Storage</td>
<td>Store at 25°C (77°F); excursions permitted 15° to 30°C (59° to 86°F). Store in the original package, protect from moisture, and keep the bottle tightly closed. Do not remove desiccant</td>
</tr>
</tbody>
</table>

3 Page(s) of Draft Labeling have been Withheld in Full as b4 (CCI/TS) immediately following this page
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

RACHNA KAPOOR
04/22/2014

YELENA L MASLOV
04/22/2014
RPM FILING REVIEW
(Including Memo of Filing Meeting)
To be completed for all new NDAs, BLAs, and Efficacy Supplements [except SE8 (labeling change with clinical data) and SE9 (manufacturing change with clinical data)]

<table>
<thead>
<tr>
<th>Application Information</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA # 205551</td>
<td>NDA Supplement #:S- 0</td>
</tr>
<tr>
<td>BLA#</td>
<td>BLA Supplement #</td>
</tr>
<tr>
<td>Efficacy Supplement Type SE-</td>
<td></td>
</tr>
<tr>
<td>Proprietary Name:</td>
<td>Established/Proper Name: GSK2619619 (abacavir sulfate, dolutegravir, and lamivudine 600/50/300 mg)</td>
</tr>
<tr>
<td>Dosage Form: tablets</td>
<td>Strengths: 600/50/300 mg</td>
</tr>
<tr>
<td>Applicant: ViiV Healthcare Company</td>
<td></td>
</tr>
<tr>
<td>Agent for Applicant (if applicable):</td>
<td></td>
</tr>
<tr>
<td>Date of Application: 10/22/2013</td>
<td></td>
</tr>
<tr>
<td>Date of Receipt: 10/22/2013</td>
<td></td>
</tr>
<tr>
<td>Date clock started after UN:</td>
<td></td>
</tr>
<tr>
<td>PDUFA Goal Date: 08/22/2014</td>
<td></td>
</tr>
<tr>
<td>Action Goal Date (if different):</td>
<td></td>
</tr>
<tr>
<td>Filing Date: 12/21/2013</td>
<td></td>
</tr>
<tr>
<td>Date of Filing Meeting: 12/17/2013</td>
<td></td>
</tr>
<tr>
<td>Chemical Classification: (1,2,3 etc.) (original NDAs only) 4</td>
<td></td>
</tr>
<tr>
<td>Proposed indication(s)/Proposed change(s): Treatment of human immunodeficiency virus (HIV) infection.</td>
<td></td>
</tr>
<tr>
<td>Type of Original NDA: AND (if applicable)</td>
<td></td>
</tr>
<tr>
<td>Type of NDA Supplement:</td>
<td></td>
</tr>
<tr>
<td>If 505(b)(2): Draft the “505(b)(2) Assessment” review found at: <a href="http://inside.fda.gov/NDAC/OfficeofNewDrugs/ImmediateOffice/UCM027492">http://inside.fda.gov/NDAC/OfficeofNewDrugs/ImmediateOffice/UCM027492</a></td>
<td></td>
</tr>
<tr>
<td>Review Classification:</td>
<td></td>
</tr>
<tr>
<td>If the application includes a complete response to pediatric WR, review classification is Priority.</td>
<td></td>
</tr>
<tr>
<td>If a tropical disease priority review voucher was submitted, review classification is Priority.</td>
<td></td>
</tr>
<tr>
<td>Resubmission after withdrawal? ☐</td>
<td></td>
</tr>
<tr>
<td>Resubmission after refuse to file? ☐</td>
<td></td>
</tr>
<tr>
<td>Part 3 Combination Product? ☐</td>
<td></td>
</tr>
<tr>
<td>If yes, contact the Office of Combination Products (OCP) and copy them on all Inter-Center consults</td>
<td></td>
</tr>
<tr>
<td>Convenience kit/Co-package</td>
<td></td>
</tr>
<tr>
<td>Pre-filled drug delivery device/system (syringe, patch, etc.)</td>
<td></td>
</tr>
<tr>
<td>Pre-filled biologic delivery device/system (syringe, patch, etc.)</td>
<td></td>
</tr>
<tr>
<td>Device coated/impregnated/combined with drug</td>
<td></td>
</tr>
<tr>
<td>Device coated/impregnated/combined with biologic</td>
<td></td>
</tr>
<tr>
<td>Separate products requiring cross-labeling</td>
<td></td>
</tr>
<tr>
<td>Drug/Biologic</td>
<td></td>
</tr>
<tr>
<td>Possible combination based on cross-labeling of separate products</td>
<td></td>
</tr>
<tr>
<td>Other (drug/device/biological product)</td>
<td></td>
</tr>
</tbody>
</table>

Version: 12/09/2013

Reference ID: 3425922
<table>
<thead>
<tr>
<th>Goal Dates/Product Names/Classification Properties</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>PDUFA and Action Goal dates correct in tracking system?</td>
<td>✗</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If no, ask the document room staff to correct them immediately. These are the dates used for calculating inspection dates.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Are the proprietary, established/proper, and applicant names correct in tracking system?</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If no, ask the document room staff to make the corrections. Also, ask the document room staff to add the established/proper name to the supporting IND(s) if not already entered into tracking system.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Is the review priority (S or P) and all appropriate classifications/properties entered into tracking system (e.g., chemical classification, combination product classification, 505(b)(2), orphan drug)? For NDAs/NDA supplements, check the New Application and New Supplement Notification Checklists for a list of all classifications/properties at: <a href="http://inside.fda.gov/9003/CDER/OfficesBusinessProcessSupport/ucl163559.htm">http://inside.fda.gov/9003/CDER/OfficesBusinessProcessSupport/ucl163559.htm</a></td>
<td>✗</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If no, ask the document room staff to make the appropriate entries.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Application Integrity Policy</td>
<td>YES</td>
<td>NO</td>
<td>NA</td>
<td>Comment</td>
</tr>
<tr>
<td>Is the application affected by the Application Integrity Policy (AIP)? Check the AIP list at: <a href="http://www.fda.gov/ICECI/EnforcementActions/ApplicationIntegrityPolicy/default.htm">http://www.fda.gov/ICECI/EnforcementActions/ApplicationIntegrityPolicy/default.htm</a></td>
<td></td>
<td>✗</td>
<td></td>
<td></td>
</tr>
<tr>
<td>If yes, explain in comment column.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If affected by AIP, has OC/OMPQ been notified of the submission? If yes, date notified:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>User Fees</td>
<td>YES</td>
<td>NO</td>
<td>NA</td>
<td>Comment</td>
</tr>
<tr>
<td>Is Form 3397 (User Fee Cover Sheet) included with authorized signature?</td>
<td>✗</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### User Fee Status

If a user fee is required and it has not been paid (and it is not exempted or waived), the application is unacceptable for filing following a 5-day grace period. Review stops. Send Unacceptable for Filing (UN) letter and contact user fee staff.

<table>
<thead>
<tr>
<th>Payment for this application:</th>
</tr>
</thead>
<tbody>
<tr>
<td>□ Paid</td>
</tr>
<tr>
<td>□ Exempt (orphan, government)</td>
</tr>
<tr>
<td>□ Waived (e.g., small business, public health)</td>
</tr>
<tr>
<td>□ Not required</td>
</tr>
</tbody>
</table>

If the firm is in arrears for other fees (regardless of whether a user fee has been paid for this application), the application is unacceptable for filing (5-day grace period does not apply). Review stops. Send UN letter and contact the user fee staff.

<table>
<thead>
<tr>
<th>Payment of other user fees:</th>
</tr>
</thead>
<tbody>
<tr>
<td>□ Not in arrears</td>
</tr>
<tr>
<td>□ In arrears</td>
</tr>
</tbody>
</table>

### 505(b)(2)
(NDAs/NDA Efficacy Supplements only)

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Is the application for a duplicate of a listed drug and eligible for approval under section 505(j) as an ANDA?</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Is the application for a duplicate of a listed drug whose only difference is that the extent to which the active ingredient(s) is absorbed or otherwise made available to the site of action is less than that of the reference listed drug (RLD)? [see 21 CFR 314.54(b)(1)].</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Is the application for a duplicate of a listed drug whose only difference is that the rate at which the proposed product’s active ingredient(s) is absorbed or made available to the site of action is unintentionally less than that of the listed drug [see 21 CFR 314.54(b)(2)]?</th>
</tr>
</thead>
<tbody>
<tr>
<td>□</td>
</tr>
</tbody>
</table>

If you answered yes to any of the above questions, the application may be refused for filing under 21 CFR 314.101(d)(9). Contact the 505(b)(2) review staff in the Immediate Office of New Drugs.

Is there unexpired exclusivity on any drug product containing the active moiety (e.g., 5-year, 3-year, orphan, or pediatric exclusivity)?


If yes, please list below:

<table>
<thead>
<tr>
<th>Application No.</th>
<th>Drug Name</th>
<th>Exclusivity Code</th>
<th>Exclusivity Expiration</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

If there is unexpired, 5-year exclusivity remaining on the active moiety for the proposed drug product, a 505(b)(2) application cannot be submitted until the period of exclusivity expires (unless the applicant provides paragraph IV patent certification; then an application can be submitted four years after the date of approval.) Pediatric exclusivity will extend both of the timeframes in this provision by 6 months. 21 CFR 314.108(b)(2). Unexpired, 3-year exclusivity may block the approval but not the submission of a 505(b)(2) application.

<table>
<thead>
<tr>
<th>Exclusivity</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Does another product (same active moiety) have orphan exclusivity for the same indication? Check the Orphan Drug

<table>
<thead>
<tr>
<th></th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Designations and Approvals list at:
http://www.accessdata.fda.gov/scripts/medsearch/opd/indextime.cfm

If another product has orphan exclusivity, is the product considered to be the same product according to the orphan drug definition of sameness [see 21 CFR 316.3(b)(13)]? □ [ ]

If yes, consult the Director, Division of Regulatory Policy II, Office of Regulatory Policy

Has the applicant requested 5-year or 3-year Waxman-Hatch exclusivity? (NDAs/NDA efficacy supplements only) [ ]

If yes, # years requested: 3

Note: An applicant can receive exclusivity without requesting it; therefore, requesting exclusivity is not required.

Is the proposed product a single enantiomer of a racemic drug previously approved for a different therapeutic use (NDAs only)? □ [ ]

If yes, did the applicant: (a) elect to have the single enantiomer (contained as an active ingredient) not be considered the same active ingredient as that contained in an already approved racemic drug, and/or (b): request exclusivity pursuant to section 505(u) of the Act (per FDAAA Section 1113)? □ [ ]

If yes, contact Mary Ann Hovac, Director of Drug Information, OGD/DLPS/LRB.

Format and Content

Do not check mixed submission if the only electronic component is the content of labeling (COL). □ All paper (except for COL) [ ] All electronic □ Mixed (paper/electronic)

□ CTD □ Non-CTD □ Mixed (CTD/non-CTD)

If mixed (paper/electronic) submission, which parts of the application are submitted in electronic format?

<table>
<thead>
<tr>
<th>Overall Format/Content</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>If electronic submission, does it follow the eCTD guidance?</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
</tr>
</tbody>
</table>

If not, explain (e.g., waiver granted).

Index: Does the submission contain an accurate comprehensive index? [ ]

Is the submission complete as required under 21 CFR 314.50 (NDAs/NDA efficacy supplements) or under 21 CFR 601.2 (BLAs/BLA efficacy supplements) including: □ [ ]


Version: 12/09/2013

Reference ID: 3425922
### Forms andCertifications

Electronic forms and certifications with electronic signatures (scanned, digital, or electronic – similar to DARRTS, e.g., .s/i) are acceptable. Otherwise, paper forms and certifications with hand-written signatures must be included. Forms include: user fee cover sheet (3397), application form (356h), patent information (3542a), financial disclosure (3454/3455), and clinical trials (3674); Certifications include: debarment certification, patent certification(s), field copy certification, and pediatric certification.

<table>
<thead>
<tr>
<th>Application Form</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Is form FDA 356h included with authorized signature per 21 CFR 314.50(a)?</td>
<td>✗</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If foreign applicant, a U.S. agent must sign the form [see 21 CFR 314.50(a)(3)].</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Are all establishments and their registration numbers listed on the form/attached to the form?</td>
<td>✗</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patent Information (NDAs/NDA efficacy supplements only)</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Is patent information submitted on form FDA 3542a per 21 CFR 314.53(c)?</td>
<td>✗</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Financial Disclosure</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Are financial disclosure forms FDA 3454 and/or 3455 included with authorized signature per 21 CFR 54.4(a)(1) and (3)?</td>
<td>✗</td>
<td></td>
<td>3454</td>
<td></td>
</tr>
</tbody>
</table>

*Forms must be signed by the APPLICANT, not an Agent [see 21 CFR 54.2(g)].*

*Note: Financial disclosure is required for bioequivalence studies that are the basis for approval.*

<table>
<thead>
<tr>
<th>Clinical Trials Database</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Is form FDA 3674 included with authorized signature?</td>
<td>✗</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*If yes, ensure that the application is also coded with the supporting document category, “Form 3674.”*
<table>
<thead>
<tr>
<th>Debarment Certification</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Is a correctly worded Debarment Certification included with authorized signature?</td>
<td>☒</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>

*Certification is not required for supplements if submitted in the original application; if foreign applicant, both the applicant and the U.S. Agent must sign the certification [per Guidance for Industry: Submitting Debarment Certifications].

*Note:* Debarment Certification should use wording in FD&C Act Section 306(k)(1) i.e., “[Name of applicant] hereby certifies that it did not and will not use in any capacity the services of any person debarred under section 306 of the Federal Food, Drug, and Cosmetic Act in connection with this application.” Applicant may not use wording such as, “To the best of my knowledge…”

<table>
<thead>
<tr>
<th>Field Copy Certification (NDAs/NDA efficacy supplements only)</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>For paper submissions only: Is a Field Copy Certification (that it is a true copy of the CMC technical section) included?</td>
<td>☐</td>
<td>☐</td>
<td>☒</td>
<td>☐</td>
</tr>
</tbody>
</table>

*Field Copy Certification is not needed if there is no CMC technical section or if this is an electronic submission (the Field Office has access to the EDR).

*If maroon field copy jackets from foreign applicants are received, return them to CDR for delivery to the appropriate field office.*

<table>
<thead>
<tr>
<th>Controlled Substance/Product with Abuse Potential</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>For NMEs: Is an Abuse Liability Assessment, including a proposal for scheduling, submitted per 21 CFR 314.50(d)(5)(vii)?</td>
<td>☐</td>
<td>☐</td>
<td>☒</td>
<td>☐</td>
</tr>
</tbody>
</table>

*If yes, date consult sent to the Controlled Substance Staff:*

<table>
<thead>
<tr>
<th>Pediatrics</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>PREA</td>
<td>☒</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>

*Does the application trigger PREA?*

*If yes, notify PeRC RPM (PeRC meeting is required)*

*Note:* NDAs/BLAs/efficacy supplements for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration trigger PREA. All waiver & deferral requests, pediatric plans, and pediatric assessment studies must be

---

[http://inside.fda.gov:9003/CDER/OfficeofNewDrugs/PediatricandMaternalHealthStaff/ucm027829.htm](http://inside.fda.gov:9003/CDER/OfficeofNewDrugs/PediatricandMaternalHealthStaff/ucm027829.htm)

Version: 12/09/2013

Reference ID: 3425922
<table>
<thead>
<tr>
<th><strong>reviewed by PeRC prior to approval of the application/supplement.</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>If the application triggers PREA,</strong> are the required pediatric assessment studies or a full waiver of pediatric studies included?</td>
</tr>
<tr>
<td>□</td>
</tr>
<tr>
<td><strong>If studies or full waiver not included,</strong> is a request for full waiver of pediatric studies OR a request for partial waiver and/or deferral with a pediatric plan included?</td>
</tr>
<tr>
<td>□</td>
</tr>
<tr>
<td><strong>If no, request in 74-day letter</strong></td>
</tr>
<tr>
<td><strong>If a request for full waiver/partial waiver/deferral is included,</strong> does the application contain the certification(s) required by FDCA Section 505B(a)(3) and (4)?</td>
</tr>
<tr>
<td>□</td>
</tr>
<tr>
<td><strong>If no, request in 74-day letter</strong></td>
</tr>
<tr>
<td><strong>BPCA (NDAs/NDA efficacy supplements only):</strong></td>
</tr>
<tr>
<td>□</td>
</tr>
<tr>
<td><strong>Proprietary Name</strong></td>
</tr>
<tr>
<td>Is a proposed proprietary name submitted?</td>
</tr>
<tr>
<td>□</td>
</tr>
<tr>
<td><strong>REMS</strong></td>
</tr>
<tr>
<td>Is a REMS submitted?</td>
</tr>
<tr>
<td>□</td>
</tr>
<tr>
<td><strong>Prescription Labeling</strong></td>
</tr>
</tbody>
</table>

3 [http://inside.fda.gov:9003/CDER/OfficeofNewDrugs/PediatricandMaternalHealthStaff/ucm027837.htm](http://inside.fda.gov:9003/CDER/OfficeofNewDrugs/PediatricandMaternalHealthStaff/ucm027837.htm)
<table>
<thead>
<tr>
<th>Question</th>
<th>Yes</th>
<th>No</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Is Electronic Content of Labeling (COL) submitted in SPL format?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If no, request applicant to submit SPL before the filing date.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Is the PI submitted in PLR format?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If PL not submitted in PLR format, was a waiver or deferral requested before the application was received or in the submission? If requested before application was submitted, what is the status of the request?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If no waiver or deferral, request applicant to submit labeling in PLR format before the filing date.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All labeling (PI, PPI, MedGuide, IFU, carton and immediate container labels) consulted to OPDP?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MedGuide, PPI, IFU (plus PD) consulted to OSE/DRISK? (send WORD version if available)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carton and immediate container labels, PI, PPI sent to OSE/DMEPA and appropriate CMC review office (OBP or ONDQA)?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OTC Labeling</td>
<td>Not Applicable</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Check all types of labeling submitted.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Is electronic content of labeling (COL) submitted?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If no, request in 74-day letter.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Are annotated specifications submitted for all stock keeping units (SKUs)?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If no, request in 74-day letter.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If representative labeling is submitted, are all represented SKUs defined?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If no, request in 74-day letter.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All labeling/packaging, and current approved Rx PI (if switch) sent to OSE/DMEPA?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other Consults</td>
<td>YES</td>
<td>NO</td>
<td>NA</td>
<td>Comment</td>
</tr>
<tr>
<td>Are additional consults needed? (e.g., IFU to CDRH; QT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

If yes, specify consult(s) and date(s) sent:

<table>
<thead>
<tr>
<th>Meeting Minutes/SPAs</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>End-of Phase 2 meeting(s)?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date(s):</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-NDA/Pre-BLA/Pre-Supplement meeting(s)?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date(s): 02/27/2013</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any Special Protocol Assessments (SPAs)?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date(s):</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If yes, distribute letter and/or relevant minutes before filing meeting</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ATTACHMENT

MEMO OF FILING MEETING

DATE: 12/17/2013

BLA/NDA/Supp #: 205551

PROPRIETARY NAME:

ESTABLISHED/PROPER NAME: GSK2619619 (dolutegravir, abacavir sulfate, lamivudine)

DOSAGE FORM-STRENGTH: tablets, 600/50/300 mg

APPLICANT: Viiv

PROPOSED INDICATION(S)/PROPOSED CHANGE(S): Treatment of HIV-1

BACKGROUND: New type 4 NDA

REVIEW TEAM:

<table>
<thead>
<tr>
<th>Discipline/Organization</th>
<th>Names</th>
<th>Present at filing meeting? (Y or N)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regulatory Project Management</td>
<td>RPM: Sohail Mosaddegh</td>
<td>Y</td>
</tr>
<tr>
<td></td>
<td>CPMS/TL: Karen Winestock</td>
<td>Y</td>
</tr>
<tr>
<td>Cross-Discipline Team Leader (CDTL)</td>
<td>Kim Struble</td>
<td>Y</td>
</tr>
<tr>
<td>Clinical</td>
<td>Reviewer: Yodit Belew</td>
<td>Y</td>
</tr>
<tr>
<td></td>
<td>TL: Kim Struble</td>
<td>Y</td>
</tr>
<tr>
<td>Social Scientist Review (for OTC products)</td>
<td>Reviewer:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TL:</td>
<td></td>
</tr>
<tr>
<td>OTC Labeling Review (for OTC products)</td>
<td>Reviewer:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TL:</td>
<td></td>
</tr>
<tr>
<td>Clinical Microbiology (for antimicrobial products)</td>
<td>Reviewer: Lisa Naeger</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TL: Julian O’Rear</td>
<td></td>
</tr>
</tbody>
</table>

Version: 12/09/2013

Reference ID: 3425922
<table>
<thead>
<tr>
<th>Area</th>
<th>Reviewer</th>
<th>TL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Pharmacology</td>
<td>Stanley Au</td>
<td>Y</td>
</tr>
<tr>
<td></td>
<td>Shirley Seo</td>
<td>Y</td>
</tr>
<tr>
<td>Biostatistics</td>
<td>Tom Hammerstrom</td>
<td>Y</td>
</tr>
<tr>
<td></td>
<td>Greg Soon/Fraser Smith</td>
<td>N</td>
</tr>
<tr>
<td>Nonclinical (Pharmacology/Toxicology)</td>
<td>Mark Seaton</td>
<td>Y</td>
</tr>
<tr>
<td></td>
<td>Hanan Ghantous</td>
<td>Y</td>
</tr>
<tr>
<td>Statistics (carcinogenicity)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immunogenicity (assay/assay validation)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(for BLAs/BLA efficacy supplements)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Product Quality (CMC)</td>
<td>Maotang Zhou</td>
<td>Y</td>
</tr>
<tr>
<td></td>
<td>Steve Miller</td>
<td>Y</td>
</tr>
<tr>
<td>Quality Microbiology (for sterile products)</td>
<td>Erica Pfeiler</td>
<td>Y</td>
</tr>
<tr>
<td>CMC Labeling Review</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Facility Review/Inspection</td>
<td>Krishna Ghosh</td>
<td>Y</td>
</tr>
<tr>
<td>OSE/DMEPA (proprietary name)</td>
<td>TBD</td>
<td></td>
</tr>
<tr>
<td>OSE/DRISK (REMS)</td>
<td>TBD</td>
<td></td>
</tr>
<tr>
<td>OC/OSI/DSC/PMSB (REMS)</td>
<td>TBD</td>
<td></td>
</tr>
</tbody>
</table>
### Filing Meeting Discussion:

#### General

- **505(b)(2) filing issues:**
  - Is the application for a duplicate of a listed drug and eligible for approval under section 505(j) as an ANDA?
  - Did the applicant provide a scientific "bridge" demonstrating the relationship between the proposed product and the referenced product(s)/published literature?

  Describe the scientific bridge (e.g., BA/BE studies):

- **Per reviewers, are all parts in English or English translation?**
  - **If no,** explain:

- **Electronic Submission comments**
  - **List comments:**

#### Clinical

- **Comments:**
  - Clinical study site(s) inspections(s) needed?
  - **If no,** explain:

---

**Version:** 12/09/2013

**Reference ID:** 3425922
<table>
<thead>
<tr>
<th>Section</th>
<th>Comments:</th>
<th>Action:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advisory Committee Meeting needed?</td>
<td></td>
<td>YES Date if known:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NO</td>
</tr>
<tr>
<td></td>
<td></td>
<td>To be determined</td>
</tr>
<tr>
<td>If no, for an NME NDA or original BLA, include the reason. For example:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>o this drug/biologic is not the first in its class</td>
<td></td>
<td></td>
</tr>
<tr>
<td>o the clinical study design was acceptable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>o the application did not raise significant safety or efficacy issues</td>
<td></td>
<td></td>
</tr>
<tr>
<td>o the application did not raise significant public health questions on the role of the drug/biologic in the diagnosis, cure, mitigation, treatment or prevention of a disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abuse Liability/Potential</td>
<td>Not Applicable</td>
<td>FILE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>REFUSE TO FILE</td>
</tr>
<tr>
<td>If the application is affected by the AIP, has the division made a recommendation regarding whether or not an exception to the AIP should be granted to permit review based on medical necessity or public health significance?</td>
<td>Not Applicable</td>
<td>YES</td>
</tr>
<tr>
<td>CLINICAL MICROBIOLOGY</td>
<td>Not Applicable</td>
<td>FILE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>REFUSE TO FILE</td>
</tr>
<tr>
<td>CLINICAL PHARMACOLOGY</td>
<td>Not Applicable</td>
<td>FILE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>REFUSE TO FILE</td>
</tr>
<tr>
<td>Clinical pharmacology study site(s) inspections(s) needed?</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>BIOSTATISTICS</td>
<td>Not Applicable</td>
<td>FILE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>REFUSE TO FILE</td>
</tr>
<tr>
<td>Comments:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comments:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comments:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### NONCLINICAL (PHARMACOLOGY/TOXICOLOGY)

**Comments:**

- Not Applicable
- FILE
- REFUSE TO FILE
- Review issues for 74-day letter

### IMMUNOGENICITY (BLAs/BLA efficacy supplements only)

**Comments:**

- Not Applicable
- FILE
- REFUSE TO FILE
- Review issues for 74-day letter

### PRODUCT QUALITY (CMC)

**Comments:**

- Not Applicable
- FILE
- REFUSE TO FILE
- Review issues for 74-day letter

### Environmental Assessment

- Categorical exclusion for environmental assessment (EA) requested?
  - YES
  - NO

  *If no,* was a complete EA submitted?
  - YES
  - NO

  *If EA submitted,* consulted to EA officer (OPS)?
  - YES
  - NO

**Comments:**

### Quality Microbiology (for sterile products)

- Was the Microbiology Team consulted for validation of sterilization? *(NDAs/NDA supplements only)*
  - YES
  - NO

**Comments:**

### Facility Inspection

- Establishment(s) ready for inspection?
  - YES
  - NO

- Establishment Evaluation Request (EER/TBP-EER) submitted to OMPQ?
  - YES
  - NO

**Comments:**

Reference ID: 3425922
<table>
<thead>
<tr>
<th>Facility/Microbiology Review (BLAs only)</th>
<th>Not Applicable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comments:</td>
<td>Review issues for 74-day letter</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CMC Labeling Review</th>
<th>Review issues for 74-day letter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comments:</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>APPLICATIONS IN THE PROGRAM (PDUFA V) (NME NDAs/Original BLAs)</th>
<th>N/A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Were there agreements made at the application’s pre-submission meeting (and documented in the minutes) regarding certain late submission components that could be submitted within 30 days after receipt of the original application?</td>
<td>YES</td>
</tr>
<tr>
<td>If so, were the late submission components all submitted within 30 days?</td>
<td>YES</td>
</tr>
<tr>
<td>What late submission components, if any, arrived after 30 days?</td>
<td>YES</td>
</tr>
<tr>
<td>Was the application otherwise complete upon submission, including those applications where there were no agreements regarding late submission components?</td>
<td>YES</td>
</tr>
</tbody>
</table>
- Is a comprehensive and readily located list of all clinical sites included or referenced in the application? [YES] [NO]
- Is a comprehensive and readily located list of all manufacturing facilities included or referenced in the application? [YES] [NO]

REGULATORY PROJECT MANAGEMENT

Signatory Authority: Division Director (Debra Birnkrant)

Date of Mid-Cycle Meeting (for NME NDAs/BLAs in “the Program” PDUFA V):

21st Century Review Milestones (see attached) (listing review milestones in this document is optional):

Comments:

REGULATORY CONCLUSIONS/DEFICIENCIES

☐ The application is unsuitable for filing. Explain why:

☒ The application, on its face, appears to be suitable for filing.

Review Issues:

☐ No review issues have been identified for the 74-day letter.

☒ Review issues have been identified for the 74-day letter. List (optional):

Review Classification:

☒ Standard Review

☐ Priority Review

ACTIONS ITEMS

☐ Ensure that any updates to the review priority (S or P) and classifications/properties are entered into tracking system (e.g., chemical classification, combination product classification, 505(b)(2), orphan drug).

☐ If RTF, notify everybody who already received a consult request, OSE PM, and Product Quality PM (to cancel EER/TBP-EER).

☐ If filed, and the application is under AIP, prepare a letter either granting (for signature by Center Director) or denying (for signature by ODE Director) an exception for review.

☐ BLA/BLA supplements: If filed, send 60-day filing letter
<table>
<thead>
<tr>
<th>Action</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>If priority review:</td>
<td></td>
</tr>
<tr>
<td>• notify sponsor in writing by day 60 (For BLAs/BLA supplements: include in 60-day filing letter; For NDAs/NDA supplements: see CST for choices)</td>
<td></td>
</tr>
<tr>
<td>• notify OMPQ (so facility inspections can be scheduled earlier)</td>
<td></td>
</tr>
<tr>
<td>Send review issues/no review issues by day 74</td>
<td>✔️</td>
</tr>
<tr>
<td>Conduct a PLR format labeling review and include labeling issues in the 74-day letter</td>
<td>✔️</td>
</tr>
<tr>
<td>Update the PDUFA V DARRTS page (for NME NDAs in the Program)</td>
<td></td>
</tr>
<tr>
<td>BLA/BLA supplements: Send the Product Information Sheet to the product reviewer and the Facility Information Sheet to the facility reviewer for completion. Ensure that the completed forms are forwarded to the CDER RMS-BLA Superuser for data entry into RMS-BLA one month prior to taking an action [These sheets may be found in the CST eRoom at: <a href="http://eroom.fda.gov/eRoom/CDER2/CDERStandardLettersCommittee/0_1685f">http://eroom.fda.gov/eRoom/CDER2/CDERStandardLettersCommittee/0_1685f</a>]</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SOHAIL MOSADDEGH
12/20/2013
Application: NDA 205551

Application Type: New NDA

Name of Drug/Dosage Form: GSK2619619 (abacavir sulfate, dolutegravir, and lamivudine 600/50/300 mg) tablets

Applicant: ViiV Healthcare Company

Receipt Date: 10/22/2013

Goal Date: 08/22/2014

1. Regulatory History and Applicant’s Main Proposals
Dolutegravir was approved for the treatment of HIV-1 infection in August 2013. GSK2619619 is a Fixed Dose Combination tablet consisting of abacavir sulfate, dolutegravir, and lamivudine (600/50/300 mg) and is proposed to be indicated as a complete regimen for the treatment of HIV-1 infection.

2. Review of the Prescribing Information
This review is based on the applicant’s submitted Word format of the prescribing information (PI). The applicant’s proposed PI was reviewed in accordance with the labeling format requirements listed in the “Selected Requirements for Prescribing Information (SRPI)” checklist (see the Appendix).

3. Conclusions/Recommendations
SRPI format deficiencies were identified in the review of this PI. For a list of these deficiencies see the Appendix.

In addition, the following labeling issues were identified:

1. In the table of contents, delete the white space above the “FULL PRESCRIBING INFORMATION : CONTENTS* this will align the text in right column with the text in the left column.
2. There should not be text between a section headings and a subsection heading. Please see 6 Adverse Reactions and 7 Drug Interactions.

All SRPI format deficiencies of the PI and other labeling issues identified above will be conveyed to the applicant in the 74-day letter. The applicant will be asked to correct these deficiencies and resubmit the PI in Word format by January 22, 2014. The resubmitted PI will be used for further labeling review.

Appendix
The Selected Requirement of Prescribing Information (SRPI) is a 42-item, drop-down checklist of important format elements of the prescribing information (PI) based on labeling regulations (21 CFR 201.56 and 201.57) and guidances.

### Highlights

See Appendix A for a sample tool illustrating the format for the Highlights.

#### HIGHLIGHTS GENERAL FORMAT and HORIZONTAL LINES IN THE PI

1. **Highlights (HL)** must be in a minimum of 8-point font and should be in two-column format, with ½ inch margins on all sides and between columns.

   **Comment:**

2. The length of HL must be one-half page or less (the HL Boxed Warning does not count against the one-half page requirement) unless a waiver has been granted in a previous submission (e.g., the application being reviewed is an efficacy supplement).

   **Instructions to complete this item:** If the length of the HL is one-half page or less, then select “YES” in the drop-down menu because this item meets the requirement. However, if HL is longer than one-half page:

   - For the **Filing Period:**
     - For **efficacy supplements:** If a waiver was previously granted, select “YES” in the drop-down menu because this item meets the requirement.
     - For **NDAs/BLAs and PLR conversions:** Select “NO” because this item does not meet the requirement (deficiency). The RPM notifies the Cross-Discipline Team Leader (CDTL) of the excessive HL length and the CDTL determines if this deficiency is included in the 74-day or advice letter to the applicant.

   - For the **End-of-Cycle Period:**
     - Select “YES” in the drop-down menu if a waiver has been previously (or will be) granted by the review division in the approval letter and document that waiver was (or will be) granted.

3. A horizontal line must separate HL from the Table of Contents (TOC). A horizontal line must separate the TOC from the FPI.

4. All headings in HL must be **bolded** and presented in the center of a horizontal line (each horizontal line should extend over the entire width of the column as shown in Appendix A). The headings should be in UPPER CASE letters.

5. White space should be present before each major heading in HL. There must be no white space between the HL Heading and HL Limitation Statement. There must be no white space between the product title and Initial U.S. Approval. See Appendix A for a sample tool illustrating white space in HL.
Selected Requirements of Prescribing Information

Comment: White space should be present before each major heading in HL. The space between the product title and Initial U. S. approval date needs to be removed. White space should separate the Initial US approval information and the Boxed Warning.

YES 6. Each summarized statement or topic in HL must reference the section(s) or subsection(s) of the Full Prescribing Information (FPI) that contain more detailed information. The preferred format is the numerical identifier in parenthesis [e.g., (1.1)] at the end of each summarized statement or topic.

Comment:

YES 7. Section headings must be presented in the following order in HL:

<table>
<thead>
<tr>
<th>Section</th>
<th>Required/Optional</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Highlights Heading</td>
<td>Required</td>
</tr>
<tr>
<td>• Highlights Limitation Statement</td>
<td>Required</td>
</tr>
<tr>
<td>• Product Title</td>
<td>Required</td>
</tr>
<tr>
<td>• Initial U.S. Approval</td>
<td>Required</td>
</tr>
<tr>
<td>• Boxed Warning</td>
<td>Required if a BOXED WARNING is in the FPI</td>
</tr>
<tr>
<td>• Recent Major Changes</td>
<td>Required for only certain changes to PI*</td>
</tr>
<tr>
<td>• Indications and Usage</td>
<td>Required</td>
</tr>
<tr>
<td>• Dosage and Administration</td>
<td>Required</td>
</tr>
<tr>
<td>• Dosage Forms and Strengths</td>
<td>Required</td>
</tr>
<tr>
<td>• Contraindications</td>
<td>Required (if no contraindications must state “None.”)</td>
</tr>
<tr>
<td>• Warnings and Precautions</td>
<td>Not required by regulation, but should be present</td>
</tr>
<tr>
<td>• Adverse Reactions</td>
<td>Required</td>
</tr>
<tr>
<td>• Drug Interactions</td>
<td>Optional</td>
</tr>
<tr>
<td>• Use in Specific Populations</td>
<td>Optional</td>
</tr>
<tr>
<td>• Patient Counseling Information Statement</td>
<td>Required</td>
</tr>
<tr>
<td>• Revision Date</td>
<td>Required</td>
</tr>
</tbody>
</table>

* RMC only applies to the BOXED WARNING, INDICATIONS AND USAGE, DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, and WARNINGS AND PRECAUTIONS sections.

Comment:

HIGHLIGHTS DETAILS

Highlights Heading

YES 8. At the beginning of HL, the following heading must be bolded and should appear in all UPPER CASE letters: “HIGHLIGHTS OF PRESCRIBING INFORMATION”.

Comment:

Highlights Limitation Statement

YES 9. The bolded HL Limitation Statement must include the following verbatim statement: “These highlights do not include all the information needed to use (insert name of drug product) safely and effectively. See full prescribing information for (insert name of drug product).” The name of drug product should appear in UPPER CASE letters.

Comment:

Product Title in Highlights

YES 10. Product title must be bolded.

Comment:
Selected Requirements of Prescribing Information

Initial U.S. Approval in Highlights

YES 11. Initial U.S. Approval in HL must be **bolded**, and include the verbatim statement “**Initial U.S. Approval:**” followed by the 4-digit year.

**Comment:**

Boxed Warning (BW) in Highlights

YES 12. All text in the BW must be **bolded**.

**Comment:**

NO 13. The BW must have a heading in UPPER CASE, containing the word “**WARNING**” (even if more than one warning, the term, “**WARNING**” and not “**WARNINGS**” should be used) and other words to identify the subject of the warning (e.g., “**WARNING: SERIOUS INFECTIONS and ACUTE HEPATIC FAILURE**”). The BW heading should be centered.

**Comment:** The title is not centered

NO 14. The BW must always have the verbatim statement “**See full prescribing information for complete boxed warning.**” This statement should be centered immediately beneath the heading and appear in *italics*.

**Comment:** This statement does not appear to be centered it is flush w

YES 15. The BW must be limited in length to 20 lines (this includes white space but does not include the BW heading and the statement “**See full prescribing information for complete boxed warning.**”).

**Comment:**

Recent Major Changes (RMC) in Highlights

N/A 16. RMC pertains to only the following five sections of the FPI: BOXED WARNING, INDICATIONS AND USAGE, DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, and WARNINGS AND PRECAUTIONS. RMC must be listed in the same order in HL as the modified text appears in FPI.

**Comment:**

N/A 17. The RMC must include the section heading(s) and, if appropriate, subsection heading(s) affected by the recent major change, together with each section’s identifying number and date (month/year format) on which the change was incorporated in the PI (supplement approval date). For example, “Warnings and Precautions, Acute Liver Failure (5.1) --- 9/2013”.

**Comment:**

N/A 18. The RMC must list changes for at least one year after the supplement is approved and must be removed at the first printing subsequent to one year (e.g., no listing should be one year older than revision date).

**Comment:**

Indications and Usage in Highlights

YES 19. If a product belongs to an established pharmacologic class, the following statement is required under the Indications and Usage heading in HL: “(Product) is a (name of established pharmacologic class) indicated for (indication)”.

**Comment:**
Selected Requirements of Prescribing Information

Dosage Forms and Strengths in Highlights

YES 20. For a product that has several dosage forms (e.g., capsules, tablets, and injection), bulleted subheadings or tabular presentations of information should be used under the Dosage Forms and Strengths heading.

Comment:

Contraindications in Highlights

YES 21. All contraindications listed in the FPI must also be listed in HL or must include the statement “None” if no contraindications are known. Each contraindication should be bulleted when there is more than one contraindication.

Comment:

Adverse Reactions in Highlights

YES 22. For drug products other than vaccines, the verbatim bolded statement must be present: “To report SUSPECTED ADVERSE REACTIONS, contact (insert name of manufacturer) at (insert manufacturer’s U.S. phone number) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch”.

Comment:

Patient Counseling Information Statement in Highlights

YES 23. The Patient Counseling Information statement must include one of the following three bolded verbatim statements that is most applicable:

If a product does not have FDA-approved patient labeling:

• “See 17 for PATIENT COUNSELING INFORMATION”

If a product has FDA-approved patient labeling:

• “See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling”

• “See 17 for PATIENT COUNSELING INFORMATION and Medication Guide”

Comment:

Revision Date in Highlights

YES 24. The revision date must be at the end of HL, and should be bolded and right justified (e.g., “Revised: 9/2013”).

Comment:
Contents: Table of Contents (TOC)

See Appendix A for a sample tool illustrating the format for the Table of Contents.

YES 25. The TOC should be in a two-column format.

Comment:

YES 26. The following heading must appear at the beginning of the TOC: “FULL PRESCRIBING INFORMATION: CONTENTS”. This heading should be in all UPPER CASE letters and bolded.

Comment:

YES 27. The same heading for the BW that appears in HL and the FPI must also appear at the beginning of the TOC in UPPER CASE letters and bolded.

Comment:

YES 28. In the TOC, all section headings must be bolded and should be in UPPER CASE.

Comment:

YES 29. In the TOC, all subsection headings must be indented and not bolded. The headings should be in title case [first letter of all words are capitalized except first letter of prepositions (through), articles (a, an, and the), or conjunctions (for, and)].

Comment:

YES 30. The section and subsection headings in the TOC must match the section and subsection headings in the FPI.

Comment:

YES 31. In the TOC, when a section or subsection is omitted, the numbering must not change. If a section or subsection from 201.56(d)(1) is omitted from the FPI and TOC, the heading “FULL PRESCRIBING INFORMATION: CONTENTS” must be followed by an asterisk and the following statement must appear at the end of TOC: “*Sections or subsections omitted from the full prescribing information are not listed.”

Comment:
Full Prescribing Information (FPI)

FULL PRESCRIBING INFORMATION: GENERAL FORMAT

32. The **bolded** section and subsection headings in the FPI must be named and numbered in accordance with 21 CFR 201.56(d)(1) as noted below (section and subsection headings should be in **UPPER CASE** and **title case**, respectively). If a section/subsection required by regulation is omitted, the numbering must not change. Additional subsection headings (i.e., those not named by regulation) must also be **bolded** and numbered.

<table>
<thead>
<tr>
<th>BOXED WARNING</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 INDICATIONS AND USAGE</td>
</tr>
<tr>
<td>2 DOSAGE AND ADMINISTRATION</td>
</tr>
<tr>
<td>3 DOSAGE FORMS AND STRENGTHS</td>
</tr>
<tr>
<td>4 CONTRAINDICATIONS</td>
</tr>
<tr>
<td>5 WARNINGS AND PRECAUTIONS</td>
</tr>
<tr>
<td>6 ADVERSE REACTIONS</td>
</tr>
<tr>
<td>7 DRUG INTERACTIONS</td>
</tr>
<tr>
<td>8 USE IN SPECIFIC POPULATIONS</td>
</tr>
<tr>
<td>8.1 Pregnancy</td>
</tr>
<tr>
<td>8.2 Labor and Delivery</td>
</tr>
<tr>
<td>8.3 Nursing Mothers</td>
</tr>
<tr>
<td>8.4 Pediatric Use</td>
</tr>
<tr>
<td>8.5 Geriatric Use</td>
</tr>
<tr>
<td>9 DRUG ABUSE AND DEPENDENCE</td>
</tr>
<tr>
<td>9.1 Controlled Substance</td>
</tr>
<tr>
<td>9.2 Abuse</td>
</tr>
<tr>
<td>9.3 Dependence</td>
</tr>
<tr>
<td>10 OVERDOSAGE</td>
</tr>
<tr>
<td>11 DESCRIPTION</td>
</tr>
<tr>
<td>12 CLINICAL PHARMACOLOGY</td>
</tr>
<tr>
<td>12.1 Mechanism of Action</td>
</tr>
<tr>
<td>12.2 Pharmacodynamics</td>
</tr>
<tr>
<td>12.3 Pharmacokinetics</td>
</tr>
<tr>
<td>12.4 Microbiology (by guidance)</td>
</tr>
<tr>
<td>12.5 Pharmacogenomics (by guidance)</td>
</tr>
<tr>
<td>13 NONCLINICAL TOXICOLOGY</td>
</tr>
<tr>
<td>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</td>
</tr>
<tr>
<td>13.2 Animal Toxicology and/or Pharmacology</td>
</tr>
<tr>
<td>14 CLINICAL STUDIES</td>
</tr>
<tr>
<td>15 REFERENCES</td>
</tr>
<tr>
<td>16 HOW SUPPLIED/STORAGE AND HANDLING</td>
</tr>
<tr>
<td>17 PATIENT COUNSELING INFORMATION</td>
</tr>
</tbody>
</table>

**Comment:**

33. The preferred presentation for cross-references in the FPI is the section (not subsection) heading followed by the numerical identifier. The entire cross-reference should be in *italics* and enclosed within brackets. For example, “[see Warnings and Precautions (5.2)]” or “[see Warnings and Precautions (5.2)]”.

Reference ID: 3425930
Selected Requirements of Prescribing Information

Comment: The clinical microbiology review team has informed sponsor’s that the following cross reference be used when referencing their section of the labeling, “see Microbiology 12.4, instead of [8] [4].

N/A 34. If RMCs are listed in HL, the corresponding new or modified text in the FPI sections or subsections must be marked with a vertical line on the left edge.

Comment:

FULL PRESCRIBING INFORMATION DETAILS

FPI Heading

YES 35. The following heading must be **bolded** and appear at the beginning of the FPI: “FULL PRESCRIBING INFORMATION”. This heading should be in **UPPER CASE**.

Comment:

BOXED WARNING Section in the FPI

YES 36. In the BW, all text should be **bolded**.

Comment:

YES 37. The BW must have a heading in **UPPER CASE**, containing the word “**WARNING**” (even if more than one Warning, the term, “**WARNING**” and not “**WARNINGS**” should be used) and other words to identify the subject of the Warning (e.g., “**WARNING: SERIOUS INFECTIONS and ACUTE HEPATIC FAILURE**”).

Comment:

CONTRAINDICATIONS Section in the FPI

YES 38. If no Contraindications are known, this section must state “None.”

Comment:

ADVERSE REACTIONS Section in the FPI

YES 39. When clinical trials adverse reactions data are included (typically in the “Clinical Trials Experience” subsection of ADVERSE REACTIONS), the following verbatim statement or appropriate modification should precede the presentation of adverse reactions:

> “Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.”

Comment:

NO 40. When postmarketing adverse reaction data are included (typically in the “Postmarketing Experience” subsection of ADVERSE REACTIONS), the following verbatim statement or appropriate modification should precede the presentation of adverse reactions:

> “The following adverse reactions have been identified during post-approval use of (insert drug name). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.”

Comment: modified language excluding “[8] [4]” text
Selected Requirements of Prescribing Information

PATIENT COUNSELING INFORMATION Section in the FPI

YES 41. Must reference any FDA-approved patient labeling in Section 17 (PATIENT COUNSELING INFORMATION section). The reference should appear at the beginning of Section 17 and include the type(s) of FDA-approved patient labeling (e.g., Patient Information, Medication Guide, Instructions for Use).

Comment:

YES 42. FDA-approved patient labeling (e.g., Medication Guide, Patient Information, or Instructions for Use) must not be included as a subsection under section 17 (PATIENT COUNSELING INFORMATION). All FDA-approved patient labeling must appear at the end of the PI upon approval.

Comment:
Selected Requirements of Prescribing Information

Appendix A: Format of the Highlights and Table of Contents

HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use [DRUG NAME] safely and effectively. See full prescribing information for [DRUG NAME].

[DRUG NAME] (nonproprietary name) dosage form, route of administration, controlled substance symbol
Initial U.S. Approval: [year]

--------
WARNING: [SUBJECT OF WARNING]
See full prescribing information for complete boxed warning.
- [text]
- [text]
--------
RECENT MAJOR CHANGES
- [section (X-X)] [m/year]
- [section (X-X)] [m/year]

INDICATIONS AND USAGE
[DRUG NAME] is a [name of pharmacologic class] indicated for:
- [text]
- [text]

DOSAGE AND ADMINISTRATION
- [text]
- [text]

DOSAGE FORMS AND STRENGTHS
- [text]

CONTRAINDICATIONS
- [text]
- [text]

WARNINGS AND PRECAUTIONS
- [text]
- [text]

ADVERSE REACTIONS
Most common adverse reactions (incidence > x%) are [text]. To report SUSPECTED ADVERSE REACTIONS, contact [name of manufacturer] at [phone #] or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS
- [text]
- [text]

USE IN SPECIFIC POPULATIONS
- [text]
- [text]

See 17 for PATIENT COUNSELING INFORMATION [and FDA-approved patient labeling OR and Medication Guide].
Revised: [m/year]

FULL PRESCRIBING INFORMATION: CONTENTS*
WARNING: [SUBJECT OF WARNING]
1 INDICATIONS AND USAGE
  1.1 [text]
  1.2 [text]
2 DOSAGE AND ADMINISTRATION
  2.1 [text]
  2.2 [text]
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
  5.1 [text]
  5.2 [text]
6 ADVERSE REACTIONS
  6.1 [text]
  6.2 [text]
7 DRUG INTERACTIONS
  7.1 [text]
  7.2 [text]
8 USE IN SPECIFIC POPULATIONS
  8.1 Pregnancy
  8.2 Labor and Delivery
  8.3 Nursing Mothers
  8.4 Pediatric Use
  8.5 Geriatric Use

9 DRUG ABUSE AND DEPENDENCE
  9.1 Controlled Substance
  9.2 Abuse
  9.3 Dependence
10 OVERDOSEAGE
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
  12.1 Mechanism of Action
  12.2 Pharmacodynamics
  12.3 Pharmacokinetics
  12.4 Microbiology
  12.5 Pharmacogenomics
13 NONCLINICAL TOXICOLOGY
  13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
  13.2 Animal Toxicology and/or Pharmacology
14 CLINICAL STUDIES
  14.1 [text]
  14.2 [text]
15 REFERENCES
16 HOW SUPPLIED/STORAGE AND HANDLING
17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed.

44 Page(s) of Draft Labeling have been Withheld in Full as b4 (CCI/TS) immediately following this page

SRPI version 3  October 2013  Page 10 of 10

Reference ID: 3425930
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SOHAIL MOSADDEGH
12/20/2013